Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  • End date
    Dec 30, 2029
  • participants needed
  • sponsor
Updated on 18 July 2021
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (1.4 mi away) Contact
+185 other location


The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment.


Eligible participants will be those diagnosed with HER2-positive (IHC 3+ or ISH+), metastatic breast cancer, who have received no prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer.

The study aims to evaluate the efficacy, and safety of trastuzumab deruxtecan, alone or with pertuzumab compared with the standard of care treatment (taxane [docetaxel or paclitaxel], trastuzumab and pertuzumab). This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the cancer affects patients' quality of life.

Condition Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic, Breast Cancer; HER2-positive; Metastatic
Treatment Placebo, Trastuzumab, Pertuzumab, Taxane, Trastuzumab deruxtecan
Clinical Study IdentifierNCT04784715
Last Modified on18 July 2021


Yes No Not Sure

Inclusion Criteria

Patients must be 18 years of age
Pathologically documented breast cancer that
is advanced or metastatic
is locally assessed and prospectively centrally confirmed as HER2-positive (IHC3+ or ISH+)
is documented by local testing as hormone receptor (HR)-positive or HR-negative disease in the metastatic setting
No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis
Has protocol-defined adequate organ and bone marrow function

Exclusion Criteria

Ineligible for any of the agents on the study
Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with subject's participation or study results
Patients with spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases or treated brain metastases that are no longer symptomatic may be included in the study
Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note